Tuesday July 17, 2018

New Biomarker Helps Identify Cancer Chemotherapy Timing

Angiogenesis therapy is clinically used to suppress tumour growth. Adding an anti-angiogenic drug can boost an anticancer drug's effectiveness

0
//
35
Biomarker can be used to decide timing fro chemotherapy.
Republish
Reprint

In ray of hope for doctors to identify the tumour normalising period for effective timing of anti-cancer drug treatment, a team of researchers have discovered a new biomarker that can visualise the activity of blood vessels.

Angiogenesis, the formation of new blood vessels, is essential for tumour growth. The team from Osaka University in Japan, in a paper reported in The American Journal of Pathology, described a vascular stabilization biomarker that can visualize blood vessel activity, thus optimising the timing of anticancer therapies including anti-angiogenics.

Chronic diseases are not yet included in cancer prevention schemes.
This can help cancer patients greatly.

Combination therapy using angiogenesis inhibitors and anticancer drugs can improve drug delivery into tumour tissues and prolong progression-free survival. “Vascular normalisation by angiogenesis inhibitors, such as vascular endothelial growth factor (VEGF) signaling inhibitors, is a promising method for improvement of chemotherapy.

“However, it is unclear how we can recognise the ‘window of opportunity’ for the tumour vascular normalising period for effective timing of anti-cancer drug treatment. Therefore, biomarkers delineating this window are essential,” explained Nobuyuki Takakura, Professor at Research Institute for Microbial Diseases, Osaka University.

Also Read: What We Know About Cancer Risk and Coffee

Angiogenesis therapy is clinically used to suppress tumour growth. Adding an anti-angiogenic drug can boost an anticancer drug’s effectiveness. Basic research indicates that anti-angiogenic therapy allows the blood vessels to return to quiescence and “normalise” so that the anti-cancer drug can penetrate the tumour more effectively. IANS

Click here for reuse options!
Copyright 2018 NewsGram

Next Story

Omega-3 Fatty Acids in Diet can Prevent Cancer From Spreading

While dietary consumption of omega-3 fatty acids can lead to EDP-EAs, for those with cancer, something concentrated and fast acting is needed

0
The results showed that the endocannabinoids slowed the growth of tumours and blood vessels, inhibited the cancer cells from migrating and caused cancer cell death.
The results showed that the endocannabinoids slowed the growth of tumours and blood vessels, inhibited the cancer cells from migrating and caused cancer cell death. (IANS)

While eating foods rich in omega-3 fatty acids, such as fatty fish, certain nuts and seeds, have been known to prevent heart diseases and arthritis, a new research, led by one of Indian-origin, showed that omega-3 fatty byproducts may also have anti-cancer effects.

The new study, led by Aditi Das from University of Illinois at Urbana-Champaign, US, showed that when the human body metabolises omega-3 fatty acids, it produces a class of molecules called endocannabinoid epoxides, or EDP-EAs. These have anti-inflammatory properties and can inhibit cancer’s growth and spread.

The EDP-EAs have similar properties to cannabinoids found in marijuana — but without the psychotropic effects — and they target the same receptor in the body that cannabis does.

“We have a built-in endocannabinoid system which is anti-inflammatory and pain-reducing. Now we see it is also anti-cancer, stopping the cells from proliferating or migrating,” said study leader Aditi Das from University of Illinois at Urbana-Champaign.

The higher concentrations of EDP-EAs did kill cancer cells, but not as effectively as other chemotherapeutic drugs on the market.
The higher concentrations of EDP-EAs did kill cancer cells, but not as effectively as other chemotherapeutic drugs on the market. Pixabay

“These molecules could address multiple problems: cancer, inflammation and pain,” Das added.

For the study, published in the Journal of Medicinal Chemistry, the team studied the effect of the molecule in mice with tumours of osteosarcoma — a bone cancer that is not only painful but also difficult to treat.

The results showed that the endocannabinoids slowed the growth of tumours and blood vessels, inhibited the cancer cells from migrating and caused cancer cell death.

The higher concentrations of EDP-EAs did kill cancer cells, but not as effectively as other chemotherapeutic drugs on the market. But, the compounds slowed tumour growth by inhibiting new blood vessels from forming to supply the tumour with nutrients. They also prevented interactions between the cells, and most significantly, they appeared to stop cancerous cells from migrating.

Also Read: Cancer-Causing Chemical Found In Odisha Fish Sample

While dietary consumption of omega-3 fatty acids can lead to EDP-EAs, for those with cancer, something concentrated and fast acting is needed, Das said.

“That’s where the endocannabinoid epoxide derivatives come into play – you could make a concentrated dose of the exact compound that’s most effective against the cancer. You could also mix this with other drugs such as chemotherapies,” she added. (IANS)